Symfi Dosage

Testing Prior to Initiation and During Treatment with SYMFI

Prior to initiation of SYMFI, test patients for hepatitis B virus infection.

It is recommended that serum creatinine, serum phosphorus, estimated creatinine clearance, urine glucose, and urine protein be assessed before initiating SYMFI and during therapy in all patients as clinically appropriate.

Monitor hepatic function prior to and during treatment with SYMFI.

Recommended Dosage for Adult and Pediatric Patients Weighing at Least 40 kg

SYMFI is a three-drug fixed-dose combination product containing 600 mg of efavirenz (EFV), 300 mg of lamivudine (3TC), and 300 mg of tenofovir disoproxil fumarate (TDF). The recommended dosage of SYMFI in HIV-1-infected adults and pediatric patients who weigh at least 40 kg, and can swallow a solid tablet, is one tablet taken orally once daily. SYMFI tablets should be taken on an empty stomach, preferably at bedtime. Dosing at bedtime may improve the tolerability of nervous system symptoms.

Not Recommended in Renal Impairment

Because SYMFI is a fixed-dose combination tablet and cannot be dose adjusted, it is not recommended for patients with impaired renal function (creatinine clearance less than 50 mL/min) or patients with end-stage renal disease (ESRD) requiring hemodialysis.

Not Recommended in Moderate to Severe Hepatic Impairment

SYMFI is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C).